Pathophysiological hallmarks of glioblastoma (GM), an incurable cancer with contemporary therapy, include microvascular proliferation and VEGF-mediated angiogenesis. We and others have demonstrated that interruption of VEGF-mediated signaling results in """"""""normalization"""""""" of tumor vasculature, transforming disorganized, dilated, leaky vessels into a more organized blood vessel network with reduced diameter and permeability. Thus, normalization may enhance delivery of chemotherapeutics and render the tumor more susceptible to cytotoxic therapies via improved oxygen delivery and diminished tumor hypoxia. In this proposal we aim to extend observations from our prior study (1R21CA117079, Batchelor-PI) in which we demonstrated, via serial non-invasive MRI techniques, that AZD2171, an oral, pan-VEGF receptor tyrosine kinase inhibitor induces normalization of tumor vessels in recurrent GM patients. Normalization had rapid onset, was prolonged but reversible and had significant clinical and functional consequences. Increased blood levels of bFGF, SDF1 and circulating endothelial cells (CECs) correlated with tumor progression. This study was the first to identify the onset and duration of a vascular normalization """"""""window"""""""" created by an anti- angiogenic agent in any human cancer and the first to demonstrate the potential utility of blood biomarkers as predictors of tumor progression on anti-angiogenic therapy. In this proposal we aim to apply the imaging and biomarker methods to patients with newly diagnosed GM.
In Aims 1 and 2 of this proposal we will define, via application of dynamic contrast enhanced MRI; diffusion-weighted and perfusion-weighted MRI, the normalization window in newly diagnosed GM patients with the therapeutic goal of exploiting this window by combining AZD2171 with cytotoxic chemoradiation. We will determine the safety (6-12 patients) then efficacy (40 patients) of this combination in newly diagnosed GM patients. We hypothesize that this therapeutic strategy will improve survival; progression-free survival and radiographic response proportion in this patient population. Identification of the normalization window in GM patients may provide opportunities for the application of more intensive, time-dependent therapeutic strategies in the future.
In Aim 3 we will continue to explore the potential utility of tumor and serial blood biomarkers, including bFGF, SDF1 and CECs, as predictors of tumor response and patient outcome in the newly diagnosed GM population. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA129371-01
Application #
7298944
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Timmer, William C
Project Start
2007-09-01
Project End
2012-07-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$552,172
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Ina Ly, K; Vakulenko-Lagun, Bella; Emblem, Kyrre E et al. (2018) Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep 8:17062
Zhao, Yingchao; Liu, Pinan; Zhang, Na et al. (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 115:E2077-E2084
Arvanitis, Costas D; Askoxylakis, Vasileios; Guo, Yutong et al. (2018) Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc Natl Acad Sci U S A 115:E8717-E8726
Khandekar, Melin J; Jain, Rakesh (2018) Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 7:S16-S20
Zhang, Na; Chen, Jie; Ferraro, Gino B et al. (2018) Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol 299:326-333
Stylianopoulos, Triantafyllos; Munn, Lance L; Jain, Rakesh K (2018) Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer 4:292-319
Fukumura, Dai; Kloepper, Jonas; Amoozgar, Zohreh et al. (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15:325-340
Askoxylakis, Vasileios; Arvanitis, Costas D; Wong, Christina S F et al. (2017) Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors. Adv Drug Deliv Rev 119:159-174
Han, Catherine H; Batchelor, Tracy T (2017) Primary Central Nervous System Lymphoma. Continuum (Minneap Minn) 23:1601-1618
Wang, Nancy; Jain, Rakesh K; Batchelor, Tracy T (2017) New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics 14:321-332

Showing the most recent 10 out of 44 publications